High-flow oxygen ‘of no benefit’ in most ACS cases
Most patients with suspected acute coronary syndrome (ACS) don’t have better 30-day mortality outcomes when they receive high-flow oxygen, researchers say.
In the trial conducted in New Zealand 40,872 patients with suspected or confirmed ACS episodes were randomised either to receive high-flow oxygen irrespective of SpO2 (6-8L/min by face mask or 4L/min by nasal cannula) or to a low-flow oxygen protocol.